{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:08:28Z","timestamp":1779786508833,"version":"3.53.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to investigate the 12\u2014month clinical outcomes and 6\u2014month morphological changes of acute penetrating aortic ulcers (PAUs) after thoracic endovascular aortic repair (TEVAR) combined with antiplatelet (AP) drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent TEVAR for acute PAUs at the General Hospital of Northern Theater Command from January 2012 to June 2024 were included. Demographics, clinical data, and imaging characteristics were retrospectively collected. The primary outcome was major adverse events, defined as a composite of death, endoleak, aortic rupture or re-dissection, re-intervention, stroke, acute myocardial infarction, and hemorrhage (BARC\u2009\u2265\u20092 grade).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 195 patients, 59 were treated with AP drugs (AP group) and 136 without AP drugs (NAP group). There were no significant differences in preoperative demographic or imaging characteristics between the two groups. A total of 180 patients with acute PAUs underwent CTA reexamination within 6 months after TEVAR. At 6-month follow-up, the mean imaging parameters were as follows: aortic diameter at PAU, 32.44\u2009\u00b1\u20092.19\u2005mm; PAU diameter, 1.83\u2009\u00b1\u20091.77\u2005mm; PAU depth, 1.46\u2009\u00b1\u20090.96\u2005mm; and intramural hematoma (IMH) thickness, 1.16\u2009\u00b1\u20091.03\u2005mm. There were no significant differences in these aforementioned parameters between the AP and NAP groups. Compared with preoperative imaging parameters, neither group showed a significant difference in aortic diameter at PAUs; however, PAU diameter and depth were smaller in both the AP and NAP groups (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and IMH thickness was also smaller in both groups (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). During 12-month follow-up, 31 patients (15.8%) experienced a primary outcome event. The cumulative incidence of major adverse events at 30 days and 12 months was higher in the AP group than in the NAP group (5.1%\n                      <jats:italic>vs<\/jats:italic>\n                      . 4.4% at 30 days; 18.6%\n                      <jats:italic>vs<\/jats:italic>\n                      . 14.7% at 12 months), but there were no statistically significant differences between the two groups. Cox regression analysis showed that maximum aortic diameter, PAU diameter\u2009\u2265\u200910.5\u2005mm, and PAU depth\u2009\u2265\u20097.5\u2005mm were associated with major adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study indicated that AP therapy may be safe for patients with acute PAUs who underwent TEVAR. Maximum aortic diameter, PAU diameter\u2009\u2265\u200910.5\u2005mm, and PAU depth\u2009\u2265\u20097.5\u2005mm were associated with major adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1676128","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:01:52Z","timestamp":1779786112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhan-kui","family":"Du","sequence":"first","affiliation":[{"name":"Department of Cardiology, the Second Hospital Affiliated to Xi\u2019an Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-song","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-hao","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-lin","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-zeng","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0890-5096(06)60697-3","article-title":"Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations","volume":"1","author":"Stanson","year":"1986","journal-title":"Ann Vasc Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ejvs.2009.09.001","article-title":"Intramural hematoma and penetrating ulcers: indications to endovascular treatment","volume":"38","author":"Eggebrecht","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jvs.2011.08.005","article-title":"Presentation, complications, and natural history of penetrating atherosclerotic ulcer disease","volume":"55","author":"Nathan","year":"2012","journal-title":"J Vasc Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/j.athoracsur.2015.12.036","article-title":"Thoracic endovascular aortic repair for penetrating aortic ulcer: literature review","volume":"101","author":"D\u2019Annoville","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.4103\/0366-6999.215330","article-title":"Safety and necessity of antiplatelet therapy on patients underwent endovascular aortic repair with both stanford type B aortic dissection and coronary heart disease","volume":"130","author":"He","year":"2017","journal-title":"Chin Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ijcard.2011.09.013","article-title":"Percutaneous transluminal intervention and antiplatelet therapy following endovascular graft exclusion for Stanford B thoracic aortic dissection","volume":"165","author":"Jing","year":"2013","journal-title":"Int J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ejcts\/ezu386","article-title":"Interdisciplinary expert consensus on management of type B intramural haematoma and penetrating aortic ulcer","volume":"47","author":"Evangelista","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ajem.2004.10.010","article-title":"The inadvertent administration of anticoagulants to ED patients ultimately diagnosed with thoracic aortic dissection","volume":"23","author":"Davis","year":"2005","journal-title":"Am J Emerg Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejvs.2016.06.005","article-title":"Editor\u2019s choice\u2014management of descending thoracic aorta diseases","volume":"53","author":"Riambau","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1067\/mva.2002.123683","article-title":"Analysis of predictive factors for progression of type B aortic intramural hematoma with computed tomography","volume":"35","author":"Sueyoshi","year":"2002","journal-title":"J Vasc Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/eurheartj\/ehu281","article-title":"2014 ESC guidelines on the diagnosis and treatment of aortic diseases","volume":"35","author":"Erbel","year":"2014","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e014505","DOI":"10.1161\/JAHA.119.014505","article-title":"Long-term imaging evolution and clinical prognosis among patients with acute penetrating aortic ulcers: a retrospective observational study","volume":"9","author":"Yang","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11748-005-0097-4","article-title":"Penetrating atherosclerotic ulcer in the juxtarenal abdominal aorta and coronary artery disease","volume":"53","author":"Taniguchi","year":"2005","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/17085381221102785","article-title":"Penetrating aortic ulcer and aortic intramural hematoma: treatment strategy","volume":"31","author":"Shao","year":"2023","journal-title":"Vascular"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jacc.2012.11.072","article-title":"Interdisciplinary expert consensus document on management of type B aortic dissection","volume":"61","author":"Fattori","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.mayocp.2023.04.002","article-title":"Natural history and sequelae of penetrating aortic ulcer","volume":"98","author":"Julakanti","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jvs.2023.06.107","article-title":"Outcomes of symptomatic penetrating aortic ulcer and intramural hematoma in the endovascular era","volume":"78","author":"Bellomo","year":"2023","journal-title":"J Vasc Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1016\/j.jtcvs.2023.04.023","article-title":"2022 ACC\/AHA guideline for the diagnosis and management of aortic disease","volume":"166","author":"Isselbacher","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.xjon.2022.03.003","article-title":"Endovascular treatment of penetrating atherosclerotic ulcers of the arch and thoracic aorta: in-hospital and 5-year outcomes","volume":"10","author":"Murana","year":"2022","journal-title":"JTCVS Open"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1676128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:01:54Z","timestamp":1779786114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1676128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2026.1676128"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1676128","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1676128"}}